Oana Danciu, MD, is Associate Director of Clinical Research at the University of Illinois Cancer Center, a breast oncologist at UI Health and Professor in the Division of Hematology and Oncology at the University of Illinois College of Medicine Chicago. Her research is focused on breast cancer, early phase clinical trials development and experimental therapeutics. Her work has been presented at major national conferences, including the American Society of Clinical Oncology (ASCO) Breast Cancer Symposium, San Antonio Breast Cancer Symposium and ASCO Cancer Survivorship Symposium. Her extensive work includes developing a Phase I protocol with a new experimental agent, PAC-1 (first procaspase activating compound). PAC-1 is a small molecule that directly activates procaspase-3 and induces apoptosis of cancer cells. Additionally, she serves as Steering Committee Chair of the Big Ten Cancer Research Consortium (CRC). Her involvement in the Big Ten CRC Breast Cancer Working has led to collaborations outside UIC with nationally recognized breast oncologists. Her trial, “A Single Arm Phase II Study of Palbociclib in Combination with Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer,” was awarded by Pfizer as part of the ASPIRE program.
Oana Danciu, MD
Professor
Medicine, Division of Hematology/Oncology
Medicine
Research Program
Translational Oncology Program (TO)
Phone: 312-996-1581
Email: [email protected]
